ResMed lifts September quarter profit by 14%
28 October, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) said its revenue for the September quarter increased 5%, despite what CEO Mick Farrell called a "tough competitive product cycle".
Biotron posts early data from HIV/HCV trial
25 October, 2013 by Dylan Bushell-EmblingDuring a phase II trial, Biotron's (ASX:BIT) BIT225 has shown promise at enhancing antiviral activity in hard-to-treat HCV Genotype 3 patients undergoing the IFN/RVB treatment regimen.
FDA clears first drug from UWA spinout iCeutica
25 October, 2013 by Dylan Bushell-EmblingiCeutica has won FDA approval for Zorvolex, the first drug developed using a technology platform conceived at the University of Western Australia.
Allied Healthcare closes $10.4m rights offer
24 October, 2013 by Dylan Bushell-EmblingAllied Healthcare (ASX:AHZ) has raised $10.4m in a rights issue to help fund commercialisation efforts for its CardioCel heart patch.
Australian Export Council conducts in-depth survey on exports
24 October, 2013To better understand the export behaviour of Australian companies and help shape Australia's future trade agenda, the Australian Export Council is conducting Australia's International Business Survey.
Phosphagenics' oxymorphone patch storms phase I
24 October, 2013 by Dylan Bushell-EmblingShares in Phosphagenics (ASX:POH) climbed 42% after the company reported strong plasma concentrations from the first in-human trial of opioid pain patch TPM/oxymorphone.
Challenges in the biotech business
23 October, 2013 by Susan WilliamsonEstablishing a small biotech company and getting products to market are just some of the challenges facing companies in the Australian biotech sector.
Immuron granted US Travelan patent
23 October, 2013 by Dylan Bushell-EmblingImmuron (ASX:IMC) has secured a US patent covering products developed with its colostrum platform technology, as it progresses with talks to bring Travelan to the US.
pSivida shares slide after third FDA knockback
22 October, 2013 by Dylan Bushell-EmblingThe US FDA has for the third time rejected pSivida (ASX:PVA) licensee Alimera Sciences' NDA for diabetic macular edema treatment Iluvien.
Last chance to register for the biotech industry event of the year: AusBiotech 2013
22 October, 2013Brisbane will welcome more than 1000 of the brightest brains in biotechnology and innovation next week for the official launch of the AusBiotech 2013 national conference; a premier event on the Australian and Asia-Pacific calendar.
Coridon hits dosing milestone in herpes trial
17 October, 2013 by Dylan Bushell-EmblingThe 20 subjects enrolled in a trial of the HSV-2 vaccine under development at Allied Healthcare's (ASX:AHZ) Coridon have all received two out of three planned doses.
Technical guidelines for therapeutic services open for comment
17 October, 2013The Department of Health and Ageing has released draft technical guidelines for therapeutic services, open for consultation until 23 November 2013.
iSonea teams with uHealth for AirSonea push
16 October, 2013 by Dylan Bushell-EmblingSydney-based uHealth will work with iSonea (ASX:ISN) to pursue more sales opportunities for the latter's asthma symptom monitoring device, AirSonea.
Bioeconomy in transition
16 October, 2013 by Susan WilliamsonThis year’s AusBiotech conference will focus on the transformation of the Australian biotech industry, following its evolution and the application of its bioactivity across areas such as agriculture, food technology and health. In this preview we provide a bumper sample of what’s in store for Brisbane at the end of October.
Ellex eye treatment shows promise in early AMD
15 October, 2013 by Dylan Bushell-EmblingResults from a pilot trial of Ellex Medical Lasers' (ASX:ELX) Retinal Rejuvenation Therapy (2RT) suggest the treatment could act as an early intervention therapy for AMD.
